Answers are grounded in this paper and cite their sources.
Diabetic foot ulcers (DFUs) are characterized by severe microvascular impairment, where unresolved chronic inflammation and persistent oxidative stress disrupt endothelial function and arrest angiogenesis. The collapse of the vascular niche underscores the clinical need to shift the microenvironment from inflammation to active resolution. The heme oxygenase-1 (HO-1) signaling pathway is a critical endogenous defense mechanism that mitigates reactive oxygen species (ROS) and generates vasoprotective metabolites, making it an optimal target for vascular rescue. This review explores the potential strategic repurposing of classic anti-inflammatory agents, such as locally administered glucocorticoids, aspirin-triggered pro-resolving mediators, and macrolides such as azithromycin as upstream modulators of HO-1 to reprogram the hostile DFU microenvironment. While systemic administration of these drugs often delays wound healing and risks immunosuppression, their localized therapeutic potential is immense. Consequently, we highlight the pivotal role of advanced pharmaceutical engineering, specifically macrophage-targeted nanocarriers and stimuli-responsive hydrogels, designed to localize anti-inflammatory delivery directly within the ischemic tissue. By bridging immunopharmacology and advanced drug delivery, targeting the HO-1 axis provides a potential translational framework to modulate chronic inflammation and support microvascular regeneration, while acknowledging the current challenges for clinical implementation.
No takes yet. Share an insight, caveat, or question.
Alvarez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: